ASX:PNV PolyNovo (PNV) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.38 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About PolyNovo (ASX:PNV) StockPolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.Read More Receive PNV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter. Email Address PNV Stock News HeadlinesMay 21, 2023 | finance.yahoo.comPolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 55% Above Its Share PriceMay 11, 2023 | msn.comPolyNovo (ASX:PNV) Price Target Decreased by 9.30% to 2.29June 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 5, 2023 | finance.yahoo.comWhen Will PolyNovo Limited (ASX:PNV) Become Profitable?April 18, 2023 | finance.yahoo.comPolyNovo Limited (ASX:PNV) Not Flying Under The RadarMarch 26, 2023 | americanbankingnews.comInsider Selling: PolyNovo Limited (ASX:PNV) Insider Sells A$465,322.73 in StockMarch 26, 2023 | americanbankingnews.comPolyNovo Limited (ASX:PNV) Insider David Williams Sells 305,451 SharesMarch 26, 2023 | americanbankingnews.comPolyNovo Limited (ASX:PNV) Insider Sells A$8,160,000.00 in StockJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.March 23, 2023 | fool.com.auPolyNovo share price falls 17% in two days after major insider sellingMarch 1, 2023 | msn.comASX Market Update, March 1– What You Should KnowFebruary 24, 2023 | finance.yahoo.comPolyNovo First Half 2023 Earnings: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)February 8, 2023 | msn.comWhy did ASX 300 healthcare stock Polynovo tumble 12% today?January 25, 2023 | finance.yahoo.comIs There Now An Opportunity In PolyNovo Limited (ASX:PNV)?January 17, 2023 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 0.03%January 10, 2023 | msn.com2 ASX All Ords shares cracking new 52-week highs on TuesdayJanuary 5, 2023 | msn.comAustralia stocks higher at close of trade; S&P/ASX 200 up 0.06%January 5, 2023 | finance.yahoo.comInvesting in PolyNovo (ASX:PNV) five years ago would have delivered you a 278% gainDecember 19, 2022 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 0.21%December 2, 2022 | fool.com.auUp 30% in 2022: Top broker says the PolyNovo share price can keep risingNovember 11, 2022 | finance.yahoo.comPolyNovo Limited (ASX:PNV) Is About To Turn The CornerOctober 27, 2022 | fool.com.auGuess which ASX All Ords share turned a $30,000 investment into $1 millionOctober 10, 2022 | finance.yahoo.comBullish PolyNovo Limited (ASX:PNV) insiders were rewarded last week as their AU$6.4m investment inflated to AU$9.8mOctober 5, 2022 | fool.com.auPolyNovo share price surges 13% on record quarterSeptember 22, 2022 | finance.yahoo.comThere's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On CapitalSeptember 19, 2022 | fool.com.auPolyNovo share price jumps 11% on FDA updateSeptember 16, 2022 | fool.com.auPolynovo share price halted amid FDA newsSee More Headlines Industry, Sector and Symbol Stock ExchangeASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:PNV CUSIPN/A CIKN/A Webwww.polynovo.com.au Phone61 3 8681 4050FaxN/AEmployees122Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.63Net Income$-6,630,000.00 Net Margins-12.49% Pretax MarginN/A Return on Equity-15.99% Return on Assets-4.84% Debt Debt-to-Equity Ratio28.44 Current Ratio5.85 Quick Ratio1.58 Sales & Book Value Annual Sales$53.12 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow207.50 Book ValueA$0.09 per share Price / BookN/AMiscellaneous Outstanding Shares689,830,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.45 Key ExecutivesMr. Jan-Marcel Gielen C.A.CFO & Company Sec.Dr. David McQuillan Ph.D.Chief Technical & Scientific OfficerMr. Swami Raote BPHARMM.B.A., CEO & DirectorMr. Ahmed HassanDirector of OperationsMs. Teena ChadhaAPAC Marketing & Distributor Mang.Ms. Monica BenykHR Mang.Dr. Tim MoorePrincipal ScientistMr. Edward GraubartSr. VP of Sales & Marketing (Americas)More ExecutivesKey Competitors3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CURAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAbzenaLON:ABZAView All CompetitorsInsidersDavid WilliamsSold 227,653 sharesTotal: $465,322.73 ($2.04/share)David WilliamsSold 305,451 sharesTotal: $632,589.02 ($2.07/share)David WilliamsSold 4,000,000 sharesTotal: $8.16 M ($2.04/share)Bruce RathieBought 200,000 shares on 2/16/2023Total: $380,000.00 ($1.90/share)David WilliamsBought 42,527 shares on 10/14/2022Total: $71,700.52 ($1.69/share)View All Insider Transactions PNV Stock - Frequently Asked Questions What other stocks do shareholders of PolyNovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyNovo investors own include Immutep (IMMP), Rural Funds Group (RFF), Vanguard FTSE Pacific ETF (VPL), UQM Technologies (UQM), Tesla (TSLA), Starpharma (SPL), Moelis Australia (MOE), iSignthis (ISX), Align Technology (ALGN) and Acasti Pharma (ACST). What is PolyNovo's stock symbol? PolyNovo trades on the ASX under the ticker symbol "PNV." How much money does PolyNovo make? PolyNovo (ASX:PNV) has a market capitalization of $0.00 and generates $53.12 million in revenue each year. The company earns $-6,630,000.00 in net income (profit) each year or A($0.01) on an earnings per share basis. How many employees does PolyNovo have? The company employs 122 workers across the globe. How can I contact PolyNovo? The official website for the company is www.polynovo.com.au. The company can be reached via phone at 61 3 8681 4050. This page (ASX:PNV) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyNovo Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.